# AlphaNavi Pharma

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/alphanavi-pharma

- Industry: Pharmaceuticals
- Headquarters: Suita-shi, Japan
- Website: www.alphanavi.com
- Total disclosed funding: $13M
- Latest round: Series B (Mar 1, 2023)
- Investors on record: 6

## About

Based in Japan, AlphaNavi Pharma focuses on the research and development of innovative pharmaceutical solutions to alleviate chronic pain and address specific medical conditions, enhancing patient quality of life.AlphaNavi Pharma was founded in 2019 and is headquartered in Suita-shi, Japan. The company specializes in developing pharmaceutical products, particularly targeting chronic pain and specific conditions such as Familial Infantile Episodic Limb Pain. In March 2023, AlphaNavi Pharma successfully raised JPY 610 million in Series B funding, bringing the total amount raised to JPY 610 million. The latest round of funding involved prominent investors including Chushin Venture Capital and Sumitomo Dainippon Pharma. The firm has completed 2 funding deals to date and currently boasts a valuation of JPY 3,173.718 million.AlphaNavi Pharma Inc. specializes in the research and development of innovative pharmaceutical products aimed at alleviating chronic and discomforting pain, as well as addressing specific medical conditions such as Familial Infantile Episodic Limb Pain. Their core product offerings include novel drugs in various stages of clinical development, prominently featuring DSP-3905, which targets neuropathic pain. The company serves a diverse client base, including healthcare providers, hospitals, and research institutions across various markets, with a focus on Japan.AlphaNavi Pharma's revenue is primarily generated through partnerships and collaborations within the pharmaceutical sector, particularly focused on the development and commercialization of their drug candidates. The company collaborates with healthcare institutions and pharmaceutical partners to establish agreements that facilitate the distribution of their innovative treatments. Pricing strategies for their flagship products align with industry standards and are designed to provide accessible solutions to healthcare providers while ensuring economic viability for the firm.In March 2023, AlphaNavi Pharma raised JPY 610 million in Series B funding, aimed at strengthening clinical trials and expanding their business operations. The company plans to leverage these funds to enhance the development of DSP-3905 and potentially introduce new products targeting additional medical conditions. Furthermore, AlphaNavi Pharma is exploring opportunities to expand into new geographical markets, with specific strategies targeting regions beyond Japan, aiming for broader distribution of their medical solutions.

## Funding rounds

- Series B, Mar 1, 2023, $4.5M — Nippon Venture Capital, Sumitomo Pharma, SMBC Venture Capital, Chushin Venture Capital, Kyoto University Innovation Capital, Shinsei Capital Partners
- Series A, Mar 28, 2019, $8.1M — Nippon Venture Capital, Sumitomo Pharma, SMBC Venture Capital, Chushin Venture Capital, Kyoto University Innovation Capital, Shinsei Capital Partners

## Investors

- Nippon Venture Capital (https://capitalatlas.ai/funds/nippon-venture-capital) — Series A, Series B
- Sumitomo Pharma — Series A, Series B
- SMBC Venture Capital (https://capitalatlas.ai/funds/smbc-venture-capital) — Series A, Series B
- Chushin Venture Capital (https://capitalatlas.ai/funds/chushin-venture-capital) — Series A, Series B
- Kyoto University Innovation Capital (https://capitalatlas.ai/funds/kyoto-university-innovation-capital) — Series A, Series B
- Shinsei Capital Partners (https://capitalatlas.ai/funds/shinsei-capital-partners) — Series A, Series B